ArticleCell2018
Increasing T Cell Versatility with SUPRA CARs.
Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Engineering CAR-T cells for solid tumors: overcoming antigenic, trafficking, and microenvironmental barriers.Frontiers in immunology · 2026Review
- CAR-T Cell Therapy for Prostate Cancer: Current Advances and Future Perspectives.Biomedicines · 2025Review
- Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.Journal of hematology & oncology · 2025Review
- Establishing a GMP-compliant manufacturing process and phase-appropriate analytics for early development of a FiCAR T-cell product with a novel CAR spacer.Scientific reports · 2025Article
- Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors.Cancers · 2024Review
- CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges.Infectious diseases & immunity · 2024Article
- Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control.Science advances · 2024Review
- Programmable synthetic receptors: the next-generation of cell and gene therapies.Signal transduction and targeted therapy · 2024Review
- Intelligent tunable CAR-T cell therapy leads the new trend.Synthetic and systems biotechnology · 2023Review
- Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer.Current issues in molecular biology · 2023Review
- Bringing cell therapy to tumors: considerations for optimal CAR binder design.Antibody therapeutics · 2023Review
- Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies.Translational oncology · 2022Review
- Emerging CAR T Cell Strategies for the Treatment of AML.Cancers · 2022Review
- Review
- Cellular immunotherapies for cancer.Irish journal of medical science · 2021Review
- pH-responsive antibodies for therapeutic applications.Journal of biomedical science · 2021Review
- Engineering switchable and programmable universal CARs for CAR T therapy.Journal of hematology & oncology · 2019Review
- CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy.International journal of molecular sciences · 2019Review
- Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia.Journal of hematology & oncology · 2019Review
- Cytokine release syndrome: grading, modeling, and new therapy.Journal of hematology & oncology · 2018Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR) T cells offer a promising treatment option for advanced cancers resistant to standard therapy. Here, Cho et al. report a split-CAR design that enables the engineering of multi-feature CAR-T cells, aiming to address current challenges limiting the safety and efficacy of CAR-T cells for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.